Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

685TiP - A phase I, multicenter trial (“KinLET”) of [177Lu]Lu-edotreotide for treatment of somatostatin receptor positive solid tumors or lymphoma, in patients two to less than 18 years of age

Date

14 Sep 2024

Session

Poster session 01

Topics

Clinical Research;  Radiological Imaging;  Cancer in Adolescents and Young Adults (AYA);  Nuclear Medicine and Clinical Molecular Imaging;  Targeted Therapy;  Cancer in Older Adults

Tumour Site

Bone Sarcomas;  Neuroendocrine Neoplasms;  Central Nervous System Malignancies

Presenters

Maria Cristina Mata Fernandez

Citation

Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc1589

Authors

M.C. Mata Fernandez1, K.J. Cohen2, S. Melnyk3, A. Rotger3, T. Thevenet4

Author affiliations

  • 1 Pediatric Oncohematology Unit, Pediatric Department, Hospital General Universitario Gregorio Marañón, 28007 - Madrid/ES
  • 2 The Sidney Kimmel Cancer Center At Johns Hopkins, Johns Hopkins Hospital, 21287 - Baltimore/US
  • 3 Clinical Development, ITM Isotope Technologies Munich SE, 85748 - Garching/DE
  • 4 Diagnostic Development, ITM Isotope Technologies Munich SE, 85748 - Garching/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 685TiP

Background

Targeted Radiopharmaceutical Therapy (RPT) with [177Lu]Lu-edotreotide is being explored as treatment option for patients with relapsed/refractory somatostatin receptor (SSTR)-positive tumors, including neuroendocrine tumors, CNS-tumors, lymphoma, rhabdomyosarcoma, peripheral primitive neuroectodermal tumors and gastrointestinal sarcoma tumors.

Trial design

KinLET is an open-label, multicenter, phase I trial aiming to determine the appropriate dose based on the safety profile and the pharmacokinetics (PK) of [177Lu]Lu-edotreotide targeted RPT in pediatric patients with SSTR-positive tumors. Further objectives include the assessment of preliminary anti-tumor activity by tumor type, safety and dosimetry evaluations. Up to 100 MBq/kg or 7.5 GBq/75 kg for each treatment cycle will be studied. Dosage of [177Lu]Lu-edotreotide will be adjusted based on the patient's weight as well as dosimetry in a subset of patients and applied sequentially in each cohort to not exceed a total absorbed dose of 23 Gy and 2 Gy to kidneys and bone marrow, respectively. [177Lu]Lu-edotreotide dosimetry is planned to be evaluated by single-photon emission computed tomography/low dose computed tomography; whole body planar imaging and blood radioactivity measurements at specific intervals, along with safety and preliminary efficacy parameters. It is planned to include at least 20 participants in three sequential age cohorts: (1) ≥12 to <18 years old; (2) ≥6 years to <12 years old; (3) ≥2 to <6 years old (minimum of six participants in each age cohort). The opening of the 2nd and 3rd cohort will depend on the recruitment of at least four participants with dosimetry and safety data for cycle 1 of the previous cohort. Treatment will comprise two to six [177Lu]Lu-edotreotide treatment cycles every eight weeks. Tumor assessment and follow-up evaluation by anatomical and functional imaging is performed within the treatment period and the first two years of the five-year follow-up. Due to the rare incidence of SSTR-positive tumors in pediatric patients, patient recruitment is a key element in this trial.

Clinical trial identification

Editorial acknowledgement

Margret I. Moré.

Legal entity responsible for the study

ITM Solucin GmbH.

Funding

ITM Solucin GmbH.

Disclosure

S. Melnyk, T. Thevenet: Financial Interests, Institutional, Full or part-time Employment: ITM Isotope Technologies Munich SE. A. Rotger: Financial Interests, Institutional, Financially compensated role: ITM Isotope Technologies Munich SE. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.